Previous 10 | Next 10 |
Investing in penny stocks is often regarded as an effective way for new investors to make money in the market. It’s also a way to leverage small amounts of capital to make large windfalls. I won’t bore you with the details of how to make money with penny stocks. Honestly, it ...
Bargain-hunting investors might be intrigued by inexpensive shares of companies that seem to leave lots of room for growth. But just because a stock is down doesn't mean it can't fall even further. If this is your strategy, you'll want as much information as possible, as well as an extensive ope...
Sprint (NYSE: S ) +74% after judge approves T-Mobile merger . More news on: Sprint Corporation, Rexahn Pharmaceuticals, Inc., ZK International Group Co., Ltd., Stocks on the move, Read more ...
Aimed at supporting the launch of contraceptive patch Twirla if approved by the FDA, Agile Therapeutics (NASDAQ: AGRX ) has inked a $35M term loan credit facility with Perceptive Advisors. More news on: Agile Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ....
Funding to Support the Company’s Commercialization Plans for Twirla ® PRINCETON, N.J., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it has entered into a senior secured term loan credi...
Do These Make The Cut Of Penny Stocks To Buy Right Now? Penny stocks usually trade below $5, but there are other penny stocks that might be trading at even lower levels. It is possible for investors to find value from among those stocks as well but you need a good eye for quality penny stoc...
Agile Therapeutics is a US biotech company based in Princeton, New Jersey. It currently has one leading candidate, Twirla, which is a weekly, “lower dose estrogen” contraception patch for women to avoid unwanted pregnancies. Currently it is waiting for FDA’s final decision...
Going into the second month of this new year, biotech investors have a lot to look forward to. In particular, there are many promising drug candidates awaiting approval from the Food and Drug Administration (FDA), as well as a number of well-established drugs that are on the cusp of receiving ex...
Agile Therapeutics Inches Closer to PDUFA for Twirla, Looks Bullish Agile Therapeutics Inc. ( AGRX ) is, currently, waiting for the FDA decision for its lead drug candidate Twirla. The PDUFA date for the drug is set for February 16th. Despite several roadblocks faced by the proposed treatm...
Lee Enterprises (NYSE: LEE ) +55% to acquire BH Media Group’s publications and The Buffalo News for $140M. More news on: Lee Enterprises, Incorporated, Hepion Pharmaceuticals, Inc., Genprex, Inc., Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Agile Therapeutics Inc. Company Name:
AGRX Stock Symbol:
OTCMKTS Market:
Agile Therapeutics Inc. Website:
First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Pink: AGRX), a women's healthcare com...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility in First Quarter 2024 Twirla Demand Expected to Rebound in First Quarter 2...